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Abstract
Methylseleninic acid (MSeA) is a monomethylated selenium metabolite theoret-
ically derived from subsequent b-lyase or transamination reactions of dietary
Se-methylselenocysteine that has potent antitumor activity by inhibiting cell
proliferation of several cancers. Our previous studies showed that MSeA pro-
motes apoptosis in invasive prostate cancer cells in part by downregulating
hypoxia-inducible factor HIF-1a. We have now extended these studies to evalu-
ate the impact of MSeA on REDD1 (an mTOR inhibitor) in inducing cell death
of invasive prostate cancer cells in hypoxia. In both PTEN+ and PTEN− pros-
tate cancer cells we show that MSeA elevates REDD1 and phosphorylation of
AKT along with p70S6K in hypoxia. Furthermore, REDD1 induction by MSeA
is independent of AKT and the mTOR inhibition in prostate cancer cells causes
partial resistance to MSeA-induced growth reduction in hypoxia. Our data sug-
gest that MSeA induces REDD1 and inhibits prostate cancer cell growth in
hypoxia despite activation of AKT and dysregulation of mTOR.
Introduction
Hypoxia in solid tumors, and in particular those of the
prostate, offers resistance to chemotherapy and radiation
treatment modalities and can be a negative factor for sur-
vival in patients with prostate cancer [1]. Reduced oxygen
tension within the prostate induces the transcription fac-
tor, hypoxia-inducible factor (HIF)-1a [2]. Upregulation
of HIF-1a activates oncogenes and inactivates tumor sup-
pressor genes which in combination may contribute to
survival of prostate cancer cells and increase their meta-
static potential [3]. HIF-1a also enhances expression of
genes coding for growth factors and their receptors,
components of the apoptotic pathway, as well as cell-cycle
regulators [4–6]. Thus, HIF-1a is a major regulator of the
hypoxic adaptive response of prostatic tumors, which
makes HIF-1a a viable target for both chemopreventive
and chemotherapeutic strategies. To date, ongoing clinical
trials targeting HIF-1a are based primarily on blocking
angiogenesis that is a major consideration in treatment of
castration-resistant prostate disease [7, 8]. However, as
with most chemotherapeutic strategies, these approaches
appear to manifest with a number of inherent side effects.
Chemoprevention strategies that perhaps target early
destabilization of HIF may provide a more effective
approach. However, caution must be drawn with these
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approaches as well since HIF-1a, despite its importance in
tumor survival, is critical for regulating normal cells in
response to transient conditions of hypoxia.
Expression of the transcription factor, REDD1 (regulated
in development and DNA damage response-1) results in a
negative regulation of the phosphatidylinositol 3-kinase
(PI3K)- AKT/mammalian target of rapamycin (mTOR)
pathway. Accordingly, REDD1 is downstream of PI3K [9,
10] and regulates mTORC1 activity [11]. Moreover, the reg-
ulation of HIF-1a by REDD1 is distinct from its ability to
inhibit mTORC1 activity [12]. Genetic ablation of REDD1
potentiates proliferation- and anchorage-independent
growth particularly under hypoxic conditions.
Studies on human cancer cells have revealed that expres-
sion of REDD1 is downregulated in human cancers [12]. By
contrast, overexpression of REDD1 can be both protective
and detrimental to cells under oxidative stress [13]. REDD1
can be induced by a variety of stress conditions, such as
hypoxia, ionizing radiation, and food deprivation or energy
stress [13, 14]. Moreover, REDD1 can be induced by insulin
in adipocytes through activation of MEK/ERK pathway.
The effect of insulin appears to be associated with dimin-
ished REDD1 protein degradation, an event that is more
pronounced under hypoxic condition in the presence of
HIF-1a [15]. Most studies link REDD1 to tumor suppres-
sion due to its contributions to apoptotic cell death [13]
and to targeting forkhead box O transcription factors [16].
The exact function of REDD1 in prostate cancer is not
completely understood. Schwarzer et al. [9] demonstrated
a requirement of REDD1 gene for prostate tumorigenesis
and another study [17] reported elevation in REDD1 pro-
tein-induced apoptosis in prostate cancer cells. It appears
that prostate cells harboring wild-type p53 can upregulate
expression of REDD1 in response to DNA damage,
whereas in cells with mutated or dysfunctional p53,
REDD1 is not targeted. By contrast, exposure of prostate
cells to alkylating agents and hypoxia, REDD1 expression
is induced by HIF-1a and can negatively regulate mTOR
activity in prostate cancer cells.
The ability of reactive oxygen species (ROS) to promote
HIF-1a stabilization suggests that the use of antioxidants
can suppress tumorigenesis through modulation of HIF-1a
[18]. In a similar fashion, REDD1 can regulate production
of ROS in mitochondria of embryonic fibroblast cells [12].
Thus, as HIF-1a and REDD1 are redox-responsive proteins,
changes in the intracellular redox environment with exoge-
nous antioxidants would be expected to enhance their
impact on apoptosis and growth inhibition.
Several experimental and epidemiology studies, as well as
clinical intervention trials have supported the hypothesis
that selenium-enriched diets can reduce the risk of prostate
cancer [19–27]. Important features of organoselenium
compounds have been identified that relate directly to their
chemopreventive properties particularly in prostate cancer
cells, such as antioxidants, inhibitors of growth and andro-
gen reactivity, regulators of signal proteins and apoptotic
inducers, and modulators of gene expression [28–30].
These and other anticancer mechanisms ascribed to orga-
noselenium compounds are markedly dependent on their
chemical forms and metabolic transformations. Chemopre-
ventive mechanisms involving methylselenol as a regulator
of redox-sensitive signal proteins and the metabolic conver-
sions of selenoamino acids into seleno-keto acids, which
function as histone deacetylase inhibitors have been
reviewed elsewhere [31–33].
A promising anticancer agent methylseleninic acid
(MSeA) has been shown to be effective in inhibiting pros-
tate cancer growth in vitro and in vivo models [24, 34,
35]. Recently, we showed that MSeA blocks growth of rat
and human prostate cancer cells [24], an effect that has
been associated with downregulation of HIF-1a even
under hypoxic conditions. Reports by others show that
inorganic sodium selenite can reduce HIF-1a and expres-
sion of vascular endothelial growth factor in melanoma
cells [36] and that HIF-1a degradation in clear cell renal
cell carcinoma by Se-methylselenocysteine is dependent
on prolyl hydroxylase (PHD2) [37].
In the current investigation we show for the first time
that MSeA elevates REDD1 expression in invasive prostate
cancer cells under hypoxic conditions and maintains lower
levels of HIF-1a. Additionally, we observe activation of
AKT and mTOR that may in part explain growth inhibition
of invasive prostate cancer cells in hypoxic condition.
Material and Methods
Cell lines and treatments
LNCaP cells were maintained in RPMI-1640 (Invitrogen,
Carlsbad, CA), DU145 cells were maintained in Minimum
Essential Medium (ATCC, Manassas, VA), and PC3 cells
were grown in F-12K medium (ATCC). These prostate
cancer cell lines were obtained from American Type Cul-
ture Collection, Manassas, VA. PC-3M cells (obtained
from Dr. Isiah Fidler at M.D. Anderson Cancer Center,
Houston, TX) were maintained in MEM (Invitrogen).
REDD1+/+ and REDD1−/− cells (obtained from Dr. Leif
Ellisen at Massachusetts General Hospital, Boston, MA)
were maintained in Dulbecco’s Minimum Essential Med-
ium (Invitrogen). All media were supplemented with 10%
FBS, and 1% penicillin–streptomycin solution unless sta-
ted otherwise. All cell types were routinely passaged
weekly and maintained in 5% CO2 at 37°C. Prior to
treatments, cells were incubated with 0.1% FBS overnight.
Next-day treatments involved repletion of control cells
with fresh medium containing 10% FBS alone and with
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MSeA (2.5–10 lmol/L) and other agents (1 lmol/L
Wortmannin, 10 nmol/L rapamycin, 100 lmol/L ascor-
bate, 2.5–5 lmol/L sodium selenite) to experimental
groups for 2 h, 4 h, 6 h or 18 h (overnight). For norm-
oxic conditions, cells were treated in incubators, accessible
to ambient air (~21% O2 levels). For experiments per-
formed under hypoxic conditions, cells were placed in
MIC-101 Modular Incubator Hypoxia Chamber (Billups-
Rothenberg Inc., Del Mar, CA) and perfused with a pre-
mixed standard gas containing 1% O2, 5% CO2, and 94%
nitrogen (GTS-Welco, Reading, PA). The airspace within
the chamber was perfused twice for 4 min each at a flow
rate of 20–25 L/min at 2 psi with the premixed gas and
the sealed chamber was placed in a 37°C incubator.
Cell growth inhibition (MTT Assay)
Human prostate cancer cells or REDD1−/− and REDD1+/+
mouse embryonic fibroblasts (MEFs) were plated at a
density of 10,000 cells/well in 96-well plates. On the fol-
lowing day, prostate cancer cells were incubated with
MSeA (2.5–10 lmol/L) or 2.5 lmol/L sodium selenite for
overnight in normoxic or hypoxic conditions as described
above. The untreated and dimethyl sulfoxide (DMSO)-
treated prostate cells or MEFs served as controls. 3-(4,5-
dimethythiazol-2-yl)-2,5-diphenyl tetrazolium bromide
(MTT) (50 lg/well) was added to cell cultures containing
phenol red-free plain medium under controlled lighting
and incubated for 4 h at 37°C in the dark. The medium
containing unreacted MTT was aspirated and DMSO
solution was added to dissolve the insoluble formazan
crystals and absorbance was read at 570 nm [38].
Immunoblotting
Control and treated cells were harvested by scraping
and washed with cold phosphate buffered saline (PBS)-
containing protease inhibitors. Nuclear and cytosolic
proteins were extracted as described previously [24].
Equal amounts of protein (50 lg) were separated on 8%,
10% or 15% SDS-PAGE gels depending upon the protein
being studied and transferred to polyvinylidene fluoride
membranes. Primary antibodies against AKT, phospho-
AKT (Ser473), phospho-GSK3a/b (Ser21/9), cleaved-
PARP (Asp214), HIF-1b, p70S6K, phosphorylated
p70S6K, RPS6, phosphorylated-RPS6, 4E-BP1 (Cell Sig-
naling, Danvers, MA), HIF-1a (R&D Systems, Minneapo-
lis, MN), REDD1 (Proteintech, Chicago, IL), Lamin B
and b-actin (Santa Cruz Biotechnology, Santa Cruz, CA)
were reacted at 1:1000 with blots. The horseradish peroxi-
dase (HRP)-conjugated anti-mouse, anti-rabbit or anti-
goat secondary antibodies (Cell Signaling) were used at a
dilution of 1:3000. Band expressions were developed using
Pierce ECL reagents (Thermo Scientific, Rockford, IL)
and the band densities were quantitated using ImageJ
analysis (National Institute of Health, Bethesda, MD).
The fold change in band densities of HIF-1a were nor-
malized to the band densities of the respective Lamin B
levels of the nuclear extracts in all samples. Fold change
in band densities of phosphorylated proteins were nor-
malized to the band densities of their respective native
protein and to b-actin levels unless indicated otherwise.
All Western blotting experiments were repeated two to
three times and representative data are shown for each.
GSH, cysteine, and methionine
determinations
PC-3M cells were treated with 5 and 10 lmol/L MSeA in
1% O2 for 2 h. Following, a wash in ice-cold PBS, cells were
pelleted at 5000g for 10 min and the supernatant fraction
removed. The pelleted cells were resuspended in ice-cold
(4°C) metaphosphoric acid (5%) and rapidly vortexed to
lyse cells and precipitate proteins. After 15 min on ice, sam-
ples were centrifuged at 5000g for 10 min and the superna-
tant solution was injected into an high-performance liquid
chromatography for determination of glutathione (GSH)
and concentrations of the sulfur-containing amino acids,
cysteine, and methionine as previously described [39].
Average values of three observations were determined for
control and MSeA-treated PC-3M cells.
Efficacy of MSeA in xenograft tumors
Athymic nude mice (males, 8 weeks of age) were subcuta-
neously inoculated with 5 9 105 PC-3M-Luc (expressing
luciferase) cells in PBS. These cells were generated in-house.
Briefly, phoenix-Ampho cells were transfected by Lipofec-
tin 2000 with pKS-neo-Luc, which encodes for the firefly
luciferase gene under a constitutively active promoter and
maintained under standard cell culture conditions. The
medium containing the replication-deficient retrovirus was
added to PC-3M cells in a 12-well plate format growing
in log phase. Cells were selected by G418 (Geneticin,
Life Technologies, Grand Island, NY) (600 lg/mL) for
1–4 weeks until significant luminescence was observed
following incubation with D-luciferin.
Mice were assigned to receive normal saline (N = 4) or
MSeA (N = 5) via intra-peritoneal (i.p.) injections with
the following doses 2.5 ppm (three injections on day 1, 4,
and 6), 4 ppm (two injections on day 8 and 11), and
5 ppm (three injections on day 13, 15, and 19). The doses
were based on our maximum-tolerated dose experiments
and as reported by others [40]. The aim of this experi-
ment was to examine the efficacy of MSeA in a dose-esca-
lation manner but we wanted to limit the selenium
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treatment to nontoxic doses (2.5–5 ppm) for mice. The
nude mice were sacrificed on day 20. The tumor measure-
ments were made on day 1 (baseline), 5, 10, and 20 post-
treatment and tumor volumes were determined using the
formula: 0.523 9 a2 9 b, where a is the smallest diameter
and b is the largest. Body weights of the control and trea-
ted mice were also measured during treatment.
Tumor burdens were assessed by Bioluminescence imag-
ing (BLI) using IVIS Spectrum (PerkinElmer, Waltham,
MA) at baseline (tumor size approximately = 200 mm3),
and at 7 and 20 days after multiple treatments with MSeA
by i.p. (as described above). Briefly, the sterile anesthesia/D-
luciferin aqueous solution (180 lL) containing a dose of
130 mg/kg ketamine, 10 mg/kg xylazine, and 150 mg/kg
potassium D-luciferin based on a mouse body weight of 20 g
was injected i.p. into each mouse. Five minutes later, mice
were laid down on the warm platform and imaging was per-
formed for 5 sec. The total flux was determined as photons/
sec. The mice were sacrificed 20 days post-treatment.
Tumor cell proliferation
(immunohistochemistry for Ki67)
The percent of Ki67-positive cells counted in triplicates in
high-power fields (4009) was used as a measure of prolifer-
ation. Briefly, formalin-fixed paraffin-embedded prostate
sections were hydrated, subjected to antigen retrieval and
incubated with anti-Ki67 antibody (M7240; Dako North
America Inc., Carpinteria, CA). Slides were developed with
using Dako EnvisionTM +/HRP polymer detection system
(K4001; Dako North America Inc.) and visualized with
3,3’-diaminobenzidine chromagen followed by hematoxy-
lin counterstain.
Statistical analysis
An analysis of variance (ANOVA) was performed to com-
pare tumor weights, tumor volumes, body weights, BLI
(photons/sec) within the MSeA and saline vehicle-treat-
ment groups. Student’s t-test was used to compare the
vehicle-treated cells with various concentrations of MSeA,
or rapamycin with and without MSeA in the MTT assay,
and immunohistochemistry for Ki67. A value of P < 0.05
was considered statistically significant for these parameters.
Results
MSeA elevates expression of REDD1 and
phosphorylation of AKT and p70S6K in
invasive prostate cancer cells in hypoxia
REDD1 regulates mTORC1 activity and the latter is criti-
cal for progression of prostate cancer disease. However,
mTORC1 regulation by REDD1 has not been well studied
in prostate cancer. We first investigated how MSeA
impacts REDD1, AKT, and p70S6K (downstream target
of mTORC1) in three different prostate cancer cell lines,
DU145 (PTEN+), PC3, and PC-3M (PTEN−) at 2, 6 h
and overnight (18 h) treatments with MSeA in hypoxia.
Additionally, we used LNCaP cells but these did not sur-
vive in hypoxia and therefore were not included in fur-
ther experiments. In DU-145 and PC-3M cells, MSeA
upregulates REDD1 protein expression at all time points
(Fig. 1A–C). However, in PC3 cells, REDD1 was increased
by MSeA at 2 and 6 h time points but was stabilized by
overnight treatment. In addition, pAKT levels are elevated
following 2 h MSeA treatment in all the three cell types
(Fig. 1A) and decrease only in DU145 cells at 6 h and
overnight MSeA treatment (Fig. 1B and C). However,
pAKT levels in control PC3 cells are increasing whereas in
PC-3M control cells the pAKT levels are decreasing as a
function of time in hypoxia. Similar observation has been
reported by other investigators [41]. Furthermore, MSeA-
induced AKT activation in PC-3M cells was confirmed by
phosphorylation of GSK3b in a dose-dependent manner
after 6 h treatment (Fig. 1D). The phosphorylated
p70S6K expression was elevated in all the prostate cancer
cell lines at all time points following treatments with
MSeA in hypoxia (Fig. 1A–C). The above events may play
a role in MSeA-induced apoptosis (as measured by
cleaved-PARP) in a dose-dependent manner in PC3,
DU145, and PC-3M cells following overnight treatment
(Fig. 1C).
MSeA induces REDD1 expression
independent of AKT in prostate cancer cells
in hypoxia
Previously published reports showed that REDD1 is
downstream of PI3K-AKT [10, 42] and is possibly
required for prostate cancer progression [9]. To deter-
mine if MSeA-induced changes in HIF-1a, REDD1, and
mTORC1 are regulated by PI3K-AKT, we specifically
decided to use PC-3M cells since these show elevated
levels of pAKT and REDD1 following MSeA treatment
at all time points. PC-3M cells were preincubated with
wortmannin (1 lmol/L) for 1 h prior to the 6 h treat-
ment with MSeA in 1% oxygen environment. MSeA
reduces HIF-1a levels in nuclear extracts in a dose-
dependent manner both in absence and presence of
wortmannin. However, decreases in HIF1a are more
pronounced when AKT is blocked (Fig. 2). Moreover,
MSeA markedly increases REDD1 expression both in the
absence and presence of wortmannin. These results indi-
cate that MSeA regulates REDD1 independent of AKT
in hypoxia.
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Concurrent with the above studies, the two downstream
targets of mTORC1, RPS6, and 4E-BP1, were also investi-
gated (Fig. 2), using wortmannin-induced blockade of
PI3K in PC-3M cells in hypoxia. MSeA was able to increase
phosphorylation of both RPS6 and 4E-BP1 in a dose-
dependent manner in hypoxia. Despite AKT inactivation in
PC-3M cells, MSeA was still able to initiate phosphoryla-
tion of RPS6 and hyper-phosphorylation 4E-BP1. However,
the phosphorylation of RPS6 was much less pronounced in
presence of wortmannin in these cells as observed when the
blot was overexposed. Additionally, MSeA promoted phos-
phorylation of AMPK in a dose-dependent manner inde-
pendent of PI3K-AKT block by wortmannin in hypoxia
(Fig. 2). However, in presence of wortmannin the extent to
which pAMPK was increased was less compared than that
in the absence of wortmannin incubation in PC-3M cells
treated with MSeA for 6 h in hypoxia. This may be
explained in part by comparatively less anabolic stress
occurring in these cells when AKT is inhibited.
mTOR inhibition in prostate cancer cells
causes partial resistance to MSeA-induced
growth reduction in hypoxia
Since we observed a dose-dependent increase in pRPS6 lev-
els in PC-3M cells, we next determined whether blocking
mTOR function would alter survival factors and cell
growth. PC-3M cells were treated with rapamycin
(10 nmol/L) in presence and absence of MSeA. As shown
in Figure 3A, MSeA inhibits HIF-1a at 2 and 6 h in the
absence of rapamycin while in its presence no appreciable
change in HIF-1a expression was observed in PC-3M cells
compared to DMSO (vehicle control) at both incubation
time points. Furthermore, in PC-3M cells that were treated
simultaneously with MSeA and rapamycin (10 nmol/L)
some resistance was observed in reducing HIF-1a levels
with rapamycin at 5 lmol/L MSeA. When cells were incu-
bated for longer duration (6 h) under hypoxic conditions,
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Figure 1. Protein expression changes in cytosolic fractions of PC3, DU145, and PC-3M cells following MSeA treatments for 2 h, 6 h and
overnight in hypoxia. The three prostate cancer cell types were stimulated with 10% FBS following an overnight starvation (0.1% FBS) in the
presence and absence of MSeA in hypoxia (1% O2). (A) Relatively increased levels of pAKT, REDD1 and pp70S6K (lower band) were observed
after 2 h of MSeA treatment in invasive prostate cancer cells in hypoxia compared to respective untreated controls. (B) MSeA treatment after 6 h
maintains elevated levels of pAKT in PC3 and PC-3M cells. REDD1 and pp70S6K levels induced by MSeA continue to increase in the three cell
types at this time point. (C) An overnight exposure of invasive prostate cancer cells to MSeA maintained high levels of pAKT in PC3 and PC-3M
cells while pAKT protein expression was marginally detectable in DU145 cells. The increase in REDD1 levels are more pronounced in the DU145
and PC-3M cells at this time point and pp70S6K expression was relatively higher in MSeA-treated cells as compared to untreated controls in each
cell line. In addition, cleaved PARP appeared in a dose-dependent manner in each of the invasive prostate cancer cells following an overnight
exposure with MSeA in hypoxia. (D) Following a 6 h treatment with MSeA in PC-3M cells, a concomitant dose-dependent elevation in pGSK3b
expression was observed. Fold change in band densities of phosphorylated proteins were normalized to the band densities of their respective
native protein and to b-actin levels. While for pp70S6K, pGSK3b and REDD1 the band densities were normalized to b-actin levels. FBS, fetal
bovine serum; MSeA, methylseleninic acid; PARP, poly ADP-ribose polymerase; REDD1, regulated in development and DNA damage 1.
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and 10 lmol/L doses of MSeA in the presence of rapamy-
cin. As observed earlier, REDD1 levels in PC-3M cells were
elevated by MSeA in (Fig. 1A and D), however, rapamycin
treatment alone decreased REDD1 levels compared to
those in DMSO control (Fig. 3B). This reduced effect of
rapamycin was also reflected by MSeA + rapamycin com-
bination when compared to MSeA treatment alone.
In the same experiment, MSeA-treated cells exhibited
increased expression of pAKT, however, in cells treated
with MSeA and rapamycin both pAKT and pRPS6 were
reduced relative to that in DMSO controls. Under similar
conditions, formation of hyperphosphorylated 4E-BP1
was reduced at 6 h by treatment with MSeA + rapamycin
but not with MSeA alone, suggesting that rapamycin is
effective in the PC-3M cells under hypoxic conditions.
In the next series of experiments, a survival assay was
used to study the effects of MSeA alone and in combina-
tion with rapamycin in invasive prostate cancer cells. PC3
and PC-3M cells were treated with MSeA alone at 5 and
10 lmol/L in normoxia or hypoxia in a 96-well MTT
assay. Separate wells of these cells were also treated with
DMSO and 10 nmol/L rapamycin alone and in combina-
tion (MSeA + rapamycin).
A dose-dependent growth inhibition was observed
following treatments with MSeA in both cell lines more
so in hypoxia than in normoxia yet for PC3 cells growth
inhibition was significant at 5 lmol/L but not at 10 lmol/
L between normoxia and hypoxia while the same trend
was observed in PC-3M cells yet significant inhibition was
observed only 10 lmol/L MSeA (Fig. 3B). These data show
that in hypoxia PC-3M cells are more sensitive to growth
inhibition compared to PC3 cells. Growth inhibition was
not observed with rapamycin alone in PC3 cells in norm-
oxia or hypoxia. By contrast, a combination of rapamycin
and MSeA (5 lmol/L but not 10 lmol/L) was more effec-
tive than rapamycin or MSeA alone in PC3 cells under
both normoxic and hypoxic conditions. In PC-3M cells,
growth inhibition was observed with rapamycin alone in
normoxia but not in hypoxia. As previously noted, the
combination of MSeA and rapamycin is more effective
than MSeA alone in normoxia. However, the addition of
rapamycin to MSeA did provide modest resistance to
growth inhibition in MSeA-treated PC-3M cells in
hypoxia, even though the cells do respond to rapamycin
downregulation of mTORC1 as shown in Figure 3A.
MSeA induces cysteine, methionine, and
GSH levels in hypoxia
Within 2 h of hypoxic conditions alone, GSH levels in PC-
3M cells increase (Table 1). When cells are treated with
MSeA, GSH, cysteine, and methionine levels continue to
– – – + + + Wortmannin (1 μmol/L) 














MSeA 0 5 μmol/L 10 μmol/L 0 5 μmol/L 10 μmol/L 
HIF-1α/lamin B 1.0 0.6 0.1 0.5 0.3 0.1
REDD1/β-actin
1.0 2.4 2.3 0.4 4.3 3.1
pAKT/AKT/β-actin
1.0 1.1 2.0 0.0 0.0 0.0
pRPS6/β-actin
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pAMPK/β-actin 1.0 1.8 2.5 0.5 1.6 1.7
Fold change
Figure 2. HIF-1a, REDD1, mTOR downstream proteins and pAMPK in PC-3M cells exposed to MSeA in presence of wortmannin in hypoxia. PC-
3M cells were pretreated for 1 h with 1 lmol/L wortmannin followed by 6 h treatment with MSeA in the absence or presence of wortmannin.
(A) Nuclear extracts were processed for HIF-1a and Lamin B xpression levels and cytosolic fractions were analyzed for REDD1, native AKT, pAKT,
pRPS6, 4E-BP1, pAMPK and b-actin protein levels. *Overexposed Western blot for visualization of pRPS6 in the presence of wortmannin. (B) Fold
changes for target proteins estimated from immunoblots in (A) compared to control untreated PC-3M cells using ImageJ analysis. The fold change
in band densities of HIF-1a were normalized to the band densities of the respective Lamin B levels of the nuclear extracts in all samples. The fold
change in band densities of pAKT was normalized to the band densities of the respective native AKT and to b-actin levels. While for REDD1,
pRPS6, 4E-BP1, and pAMPK the band densities were normalized to b-actin levels. HIF-1a, hypoxia-inducible factor-1 alpha; REDD1, regulated in
development and DNA damage 1; MSeA, methylseleninic acid.
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rise in hypoxia. These data correlate with an increase in
pp70S6K (Fig. 1A) and pRPS6 (Fig. 2) levels suggesting
that the kinases involved in phosphorylation of p70S6K
and pRPS6 may be influenced by the redox status of the






MSeA (μmol/L)       – 5     10      C      – 5      10   




MSeA (μmol/L) – 5     10      C      – 5     10   
Rapa (10 nmol/L)    – – – – +     +       + 
2 h-treatment 6 h-treatment
REDD1ND
1.0      0.4     0.2     0.5     0.7    0.6     0.1
Lamin B
1.0      0.4     0.3     0.3     0.2    0.1      0.1
1.0      1.4     2.8     1.9     0.6     1.6     2.0
1.0     1.0     1.3     1.6     0.7     0.7     0.8
1.0      0.9     1.0     1.1     0.05   0.01  0.03
1.0      1.0     0.9     1.1     0.6     0.6     0.8
1.0     1.7    2.9     4.0    3.8     3.3    2.9
1.0     1.0    1.1     1.2    1.0     0.9     0.6
1.0     0.9    1.1      0.8     0.6     0.8     0.8
B
A
Figure 3. (A) HIF-1a, REDD1, pAKT, pRPS6, 4E-BP1 levels in MSeA-treated PC-3M cells in presence of rapamycin in hypoxia. PC-3M cells were
pretreated for 1 h with rapamycin (10 nmol/L) before being exposed to 2 or 6 h treatment with MSeA. Nuclear extracts were processed for HIF-1a and
Lamin B xpression levels and cytosolic fractions were analyzed for REDD1, native AKT, pAKT, pRPS6, 4E-BP1 and b-actin protein levels. MSeA reduced
HIF-1a levels in a dose-dependent manner but in the presence of rapamycin moderate resistance occurs at the lower dose of MSeA (5 lmol/L) at 2 h. At
6 h, HIF-1a levels were considerably reduced with the combined treatment. REDD1 levels were clearly upregulated by MSeA but downregulated by
rapamycin treatment in 6 h under hypoxia. MSeA treatment of PC-3M cells in presence of rapamycin was able to rescue the REDD1 reduction. MSeA
treatment clearly induces pAKT levels after 2 h and continues up to 6 h in hypoxia. However, in the presence of rapamycin, an increase was not evident
at either time point compared to DMSO control. MSeA also increases levels of pRPS6 moderately (2 and 6 h) and rapamycin strongly blocks
phosphorylation on RPS6 compared to DMSO control (C) at 2 h and was completely eliminated by 6 h. At 2 h, the hyper-phosphorylated bands on 4E-
BP1 are upregulated following MSeA treatment but in the presence of rapamycin this band is less phosphorylated and completely disappears after 6 h
combined treatment in PC-3M cells. ND: not determined. (B) Growth inhibition of prostate cancer cells treated with MSeA in the presence or absence of
rapamycin when examined under normoxia or hypoxia. a versus b (P < 0.05), *N versus H: P < 0.05, c versus d, e versus f and g versus h: P < 0.01. The
fold change in band densities of HIF-1awere normalized to the band densities of the respective Lamin B levels of the nuclear extracts in all samples. The
fold change in band densities of pAKT and pRPS6 were normalized to the band densities of the respective native AKT and RPS6 and to b-actin levels.
While for REDD1, and 4E-BP1 the band densities were normalized to b-actin levels. HIF-1a, hypoxia-inducible factor-1 alpha; REDD1, regulated in
development and DNA damage 1; MSeA, methylseleninic acid; DMSO, dimethyl sulfoxide.
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MSeA downregulates HIF-1a in REDD1 MEFs
REDD1+/+ and REDD1−/− MEFs were treated with 5
and 10 lmol/L MSeA or 100 lmol/L ascorbate for 4 h in
hypoxia. REDD1−/− cells express high levels of HIF-1a in
hypoxia and MSeA treatment inhibits its expression much
more efficiently than does treatment with ascorbate after
4 h (Fig. 4A). Reports by others in REDD1+/+ cells show
that HIF-1a levels are elevated to a lesser extent in
hypoxia compared to that in REDD1−/− cells [12]. When
REDD1+/+ cells are treated for 4 h with MSeA (5 and
10 lmol/L), selenite (2.5 and 5 lmol/L) and ascorbate
(100 lmol/L), MSeA induces REDD1 protein levels to
greater extent than selenite and there was no change with
ascorbate (Fig. 4B). There is no appreciable change in
pRPS6 after all treatments in REDD1+/+ cells. Overnight
treatment of REDD1+/+ and REDD1−/− cells with MSeA
showed that PARP was cleaved although the extent of
cleavage in REDD1−/− cells was visualized only upon
overexposure of the blot (Fig. 4C). These results indicate
that REDD1+/+ cells are more sensitive to apoptosis by
MSeA in a dose-dependent manner compared to that of
REDD1−/− cells. This observation is further supported
Table 1. Cysteine, GSH, and methionine levels in PC-3M cells treated














Normoxia 4.19 44.83 0.71 0.88 52.76
Hypoxia 5.73 70.89 1.52 0.95 78.39
5 lmol/L
MSeA
7.98 61.66 2.07 1.02 60.93
10 lmol/L
MSeA
12.68 72.23 2.46 0.84 86.11
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Figure 4. HIF-1a and REDD1 levels in REDD1 MEFs following treatments with MSeA, Selenite and ascorbate in hypoxia. Nuclear extracts were
processed for HIF-1a and Lamin B expression levels and cytosolic fractions were analyzed for REDD1, pRPS6, cleaved-PARP and b-actin protein
levels. (A) REDD1−/− cells express high levels of HIF-1a compared to REDD1+/+ cells and MSeA downregulates HIF-1a in both cell types.
Ascorbate, on the other hand, does not show appreciable changes in HIF-1a in either cell type. (B) MSeA upregulates REDD1 protein expression in
REDD1+/+ cells. Selenite also increases REDD1 levels but to less extent and ascorbate shows no change when compared to untreated controls.
There are no appreciable changes in pRPS6 by either treatment. (C) REDD1+/+ cells are more sensitive compared to REDD1−/− cells for MSeA-
induced apoptosis as shown by cleaved-PARP. (D) Growth inhibition of REDD1+/+ and REDD1−/− cells by MSeA in normoxia compared to hypoxia
conditions. REDD1−/− cells are more resistant to growth inhibition by MSeA as compared to REDD1+/+ cells regardless of oxygen levels.
*P < 0.05, **P < 0.001 as compared to respective normoxia and hypoxia controls. The fold change in band densities of HIF-1a were normalized
to the band densities of the respective Lamin B levels of the nuclear extracts in all samples. The fold change in band densities of REDD1 and
pRPS6 were normalized to b-actin levels. HIF-1a, hypoxia-inducible factor-1 alpha; REDD1, regulated in development and DNA damage 1; MSeA,
methylseleninic acid; DMSO, dimethyl sulfoxide.
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by cell growth inhibition data shown in Figure 4D. Under
both normoxic and hypoxic condition, MSeA in
REDD1+/+ cells inhibited growth to a greater extent than
in REDD1−/− cells. In comparison of cell survival
between hypoxic and normoxic condition, both cell types
demonstrated greater growth inhibition under hypoxic
than in normoxic conditions. Although these data cannot
be extrapolated to prostate cancer cells but it is evident
from these experiments that MSeA is changing the redox
state of cells in hypoxia and thereby increasing REDD1
and decreasing HIF-1a.
MSeA reduces tumor growth of PC-3M-Luc
cells in nude mice
Although, PC3 cells have been used for xenograft model
for testing MSeA by oral route for about 49 days [43],
our intent was to investigate the efficacy of MSeA against
a highly invasive prostate cancer cell line (PC-3M).
Therefore, we decided an i.p. route of treatment for a
shorter duration. The PC-3M-Luc cells were injected sub-
cutaneously into left flanks of nude mice. Tumor volumes
showed a steady growth in control while the MSeA-trea-
ted tumors exhibited reduced volumes (P < 0.05) at the
end of the experiment (Fig. 5A). Similarly, number of
Ki67-positive cells was decreased in the tumors following
MSeA treatment (control: 123.5  2.6; MSeA:
62.7  18.4, P < 0.05). Furthermore, tumor burdens in
control and MSeA-treated mice were reflected by change
(P < 0.05) in total luminescence flux by day 20 post-
treatment (Fig. 5B). The BLI of representative mice from
control and MSeA-treated groups are shown in Figure 5C.
Body weights did not change significantly between control
and treated groups during the short-term treatment with
A B
C D
Figure 5. PC-3M-Luc tumor growth inhibition in MSeA-treated nude mice. PC-3M-Luc cells were injected s.c. into nude mice and treated with
increasing doses of MSeA (i.p.) as described in materials and methods. (A) Tumor volume is reduced by MSeA treatment at the end of study
(P < 0.05). Number of Ki67-positive cells was also reduced in tumor sections following MSeA treatment (inset). (B) Tumor burden as measured by
change in luciferase activity from baseline is reduced following MSeA treatment (P < 0.05). (C) BLI measurements from representative saline and
MSeA-treated PC-3M-Luc-bearing tumors and their respective characteristics. (D) Body weights of MSeA-treated nude mice are reduced compared
to saline-treated control mice but the changes are not statistically significant. MSeA, methylseleninic acid; BLI, bioluminescence imaging.
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MSeA (Fig. 5D). At the end of the experiment, tumor
weights were 0.91  0.54 g in control and 0.44  0.23 g
in MSeA-treated mice. Despite the apparent changes in the
mean values, differences in overall tumor weights were not
statistically significant due to large variation between
groups. These findings differ slightly from Li et al. [43]
who showed that inhibition of tumor growth occurred after
oral MSeA treatment for longer duration in xenograft mod-
els using LNCaP, DU145, and PC3 cells.
Discussion
Numerous experimental and epidemiology studies, as well
as clinical intervention trials have supported the hypothe-
sis that selenium-enriched diets can reduce the risk of
prostate cancer [19–27]. Results from more recent Sele-
nium and Vitamin E Cancer Prevention Trial (SELECT)
failed to show a beneficial effect of selenomethionine on
prostate cancer and vitamin E alone enhanced prostate
cancer significantly [44]. These data did raise the question
of selenium’s role in anticancer strategies but we have to
realize that the form of selenium being tested is critical
for a positive outcome and we need to investigate more
potent selenium-containing agents as compared to seleno-
methionine. Previously, MSeA has successfully been tested
as a promising anticancer agent in prostate cancer models
[20, 24]. Our goal, for current investigation was to study
the potential of MSeA in a highly metastatic prostate can-
cer model system and examine possible mechanism(s) by
which it inhibits growth of these cells.
In the PC-3M xenograft study, using MSeA in a dose-
escalation regimen our data demonstrate a decrease in
tumor volume, tumor burden, and tumor weights. How-
ever, the overall tumor weights were not significantly
reduced due to the short-term treatment and inter-animal
variation. But PC-3M being a highly invasive prostate
cancer model provides the opportunity to investigate the
role of MSeA on HIF-1a regulation and its downstream
targets.
In our previous report, we had documented MSeA-
induced downregulation of HIF-1a in invasive prostate
cancer cells [24]. The mechanism of HIF-1a reduction
was shown to involve a stabilization of the PHD domain.
Recently, a similar finding demonstrated that Se-meth-
ylselenocysteine inhibited HIF-1a in renal cell carcinoma
through a PHD2-dependent and Von-Hippel-Lindau-
independent degradation mechanism [37]. In the current
investigation, our goal was to determine whether MSeA
impacted REDD1 protein, a redox-sensitive downstream
target of HIF-1a. REDD1 was initially identified as a
hypoxia-regulated HIF-1a target gene involved in regula-
tion of cell survival [13]. Genetic studies revealed that
REDD1 is a hypoxia-induced regulator of mTORC1
activity [11] and as a consequence in REDD1-/- cells,
mTORC1 is not suppressed [45]. Abrogation of REDD1
enhances tumorigenesis, a process that is associated with
elevation of mitochondrial ROS which can stabilize HIF-
1a. The regulation of ROS by REDD1 is mTOR-indepen-
dent, which in the presence of antioxidants can restore
normal levels of HIF-1a. Organoselenium compounds can
affect the redox environment within cells as cited previ-
ously with GSH and we initially anticipated a decline in
REDD1 levels following treatment with MSeA in hypoxia.
Contrary to our original hypothesis, a 2-h exposure of
cells to MSeA resulted in an upregulation of REDD1 pro-
tein expression in PTEN+ and PTEN− prostate cancer cell
lines. Furthermore, MSeA was shown to sustain high lev-
els of REDD1 in DU145 and PC-3M cells until the end of
experiment in hypoxia. These results also correlate with
induction of apoptosis in prostate cancer cells by MSeA
in hypoxia as reflected by a dose-dependent cleavage of
PARP.
In studies by Horak et al. [12], a loss of REDD1
expression was observed in breast cancer tissues as the
disease progressed. However, a report by Schwarzer et al.
[9] in PC3 prostate cancer cells showed that knockdown
of REDD1 gene was able to sensitize these cells toward
apoptosis. Thus, their studies suggested that overexpres-
sion of REDD1 would diminish apoptotic elimination of
cells. By contrast, our data in DU145 and PC-3M clearly
show that REDD1 protein expression is lower in the
untreated-control prostate cancer cells but is elevated
upon MSeA treatment in a dose-dependent manner. In
fact, the elevated REDD1 levels in MSeA-treated prostate
cancer cells may be a major contributor to cell death, a
finding supported previously by Ben Sahra et al. [17]
who showed that REDD1 is required for metformin-
induced cell-cycle arrest and mTOR inhibition in prostate
cancer cells.
Although, the experiment with REDD1 MEFs cannot
be extrapolated to prostate cancer cells but using
REDD1+/+ and REDD1−/− cells, modest resistance to cell
death is observed in REDD1−/− cells as observed by
cleaved-PARP and cell growth inhibition assays. This sug-
gests that increased expression of REDD1 would facilitate
MSeA-induced apoptosis in hypoxia.
Furthermore, MSeA-induced pAKT levels starting at
2 h post-treatment in hypoxia. These data corroborate
with a concomitant increase in pGSK3b indicating AKT
is functional in PC-3M cells. Studies by others [46] clearly
demonstrate that GSK3b phosphorylates REDD1 and pro-
motes its ubiquitination. Our studies indicate that ele-
vated levels of pAKT results in inactivation of GSK3b
through phosphorylation and, therefore, may explain why
REDD1 accumulates in PC-3M cells following MSeA
treatment in hypoxia. In addition, pp70S6K levels were
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elevated early on (at 2 h treatment) by MSeA indicative
of mTORC1 activation in prostate cancer cells. Since PC3
and PC-3M cells are PTEN− it is expected that mTOR
will not be completely inhibited in hypoxia [47].
Earlier studies [9, 10] suggest that REDD1 is down-
stream of PI3K-AKT and that REDD1 inhibits mTOR
function via TSC1/2 and 14-3-3 interactions [11]. We
investigated whether REDD1 is downstream of PI3K-AKT
in invasive prostate cancer cells in hypoxic environment.
Following treatment of prostate cancer cells with the
PI3K inhibitor, wortmannin, MSeA was shown to induce
a downregulation of HIF-1a and a concomitant upregula-
tion of REDD1 protein in an apparent AKT independent
manner. As a result, an increase in REDD1 expression by
MSeA conceivably helped maintain low levels of HIF-1a
expression in these cells. Mitochondrial REDD1 is most
likely playing a role in regulation of HIF-1a as reported
earlier [12], and this regulation by REDD1 is via a nega-
tive feedback loop, which is independent of its mTOR
regulatory function.
Since AKT activation stimulates aerobic glycolysis in
cancer cells and facilitates higher energy consumption
[48], in the absence of HIF-1a, it is likely that elevated
levels of pAKT and pp70S6K promote greater energy con-
sumption under hypoxic conditions. This effect may
cause tumor cells to undergo a hypermetabolic crisis. Fol-
lowing this crisis along with elevated pAMPK, the cells do
not recover in spite of upregulation of survival signals in
hypoxia and thus experience cell death. In other words,
cells with activated AKT are more prone to ROS-induced
stress resulting in apoptosis [49, 50]. It is noteworthy that
the previous studies in human prostate cancer cells have
shown that selenium can inhibit as well as activate AKT
[51]; however, our data unequivocally show that MSeA
activates the AKT protein kinase (at early time point)
concurrent with reduction in HIF-1a expression. This
sustained oxidative stress may commit cells to apoptosis.
Alternatively, MSeA-induced downregulation of HIF-1a
in PC-3M cells may be allowing AKT activation via
mTORC2 activation. These responses in metabolic path-
ways need to be examined in future experiments.
Active mTORC1 has a number of downstream biologi-
cal effects including translation of mRNA via the phos-
phorylation of downstream targets (4E-BP1 and p70S6K).
When PC-3M cells were treated with rapamycin (an
inhibitor of mTORC1), we observed a time-dependent
decrease in pRPS6 and hyper-phosphorylated band on
4E-BP1, which was not rescued by MSeA treatment. By
contrast, rapamycin reduced REDD1 protein expression
and MSeA treatment was able to reverse the inhibition.
Our studies suggest that elevated levels of REDD1 by
MSeA contribute to the growth inhibition in PC-3M
prostate cancer cells under hypoxic conditions and that
blocking mTORC1 would offer some resistance. In other
words, elevation of both REDD1 and mTORC1 would
facilitate enhanced cell death of PC-3M cells by MSeA in
hypoxia. This is in contrast to PC3 cells in which the
combination of rapamycin and MSeA offered greater
growth inhibition compared to rapamycin or MSeA alone
in both hypoxia and normoxia. In addition, a reduction
in the levels of HIF-1a would be expected to promote a
decrease in PC-3M cell growth.
In summary, our data demonstrate that MSeA induces
REDD1 expression and promotes apoptosis in invasive
prostate cancer cells in hypoxia. These findings are asso-
ciated with a downregulation of HIF-1a and an activation
of AKT along with mTORC1 signaling facilitating MSeA-
induced growth inhibition. Understanding the mecha-
nism(s) by which MSeA affects these pathways could be
useful in inhibiting the transformation of prostate cells
observed in prostatitis to those in benign prostatic hyper-
trophy (BPH) or prostatic intraepithelial neoplasia (PIN).
The cellular transformations observed in these cells are
associated with inflammation driven by HIF-1a-promot-
ing growth events [52]. MSeA may also be used in com-
bination with chemotherapy agents for invasive and
recurrent or resistant prostate cancers, which express high
HIF-1a.
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